Literature DB >> 16828434

Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization.

William A Marston1, Stephen W Davies, Brian Armstrong, Mark A Farber, Robert C Mendes, Joseph J Fulton, Blair A Keagy.   

Abstract

OBJECTIVES: The natural history of limbs affected by ischemic ulceration is poorly understood. In this report, we describe the outcome of limbs with stable chronic leg ulcers and arterial insufficiency that were treated with wound-healing techniques in patients who were not candidates for revascularization.
METHODS: A prospectively maintained database of limb ulcers treated at a comprehensive wound center was used to identify patients with arterial insufficiency, defined as an ankle-brachial index (ABI) <0.7 or a toe pressure <50 mm Hg. Patients were treated without revascularization when medical comorbidity or anatomic considerations did not allow revascularization with acceptable risk. Ulcers were treated with a protocol emphasizing pressure relief, débridement, infection control, and moist wound healing. Risk factors analyzed for their affect on healing and amputation risk included age, gender, diabetes mellitus, chronic renal insufficiency (serum creatinine > 2.5 mg/dL), severity of ischemia measured by ABI or toe pressure, wound grade, wound size, and wound location.
RESULTS: Between January 1999 and March 2005, 142 patients with 169 limbs having arterial insufficiency and full-thickness ulceration were treated without revascularization. Mean patient age was 70.8 +/- 4.5. Diabetes mellitus was present in 70.4% of limbs and chronic renal insufficiency in 27.8%. Toe amputations or other foot-sparing procedures were performed in 28% of limbs. Overall, limb loss occurred in 37 patients. By life-table analysis, 19% of limbs required amputation < or =6 months of initial treatment and 23% at 12 months. Complete wound closure was achieved in 25% by 6 months and in 52% by 12 months. Statistical analysis showed a correlation between ABI and the risk of limb loss. In patients with an ABI <0.5, 28% and 34% of limbs experienced limb loss at 6 and 12 months, respectively, compared with 10% and 15% of limbs in patients with an ABI >0.5 (P = .01). The only risk factor associated with wound closure was initial wound size (P < .005).
CONCLUSIONS: Limb salvage can be achieved in most patients with arterial insufficiency and uncomplicated chronic nonhealing limb ulcers using a program of wound management without revascularization. Healing proceeds slowly, however, requiring more than a year in many cases. Patients with an ABI <0.5 are more likely to require amputation. Interventions designed to improve outcomes in critical limb ischemia should stratify outcomes based on hemodynamic data and should include a comparative control group given the natural history of ischemic ulcers treated in a dedicated wound program.

Entities:  

Mesh:

Year:  2006        PMID: 16828434     DOI: 10.1016/j.jvs.2006.03.026

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  50 in total

1.  Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia.

Authors:  Michael P Murphy; Jeffrey H Lawson; Brian M Rapp; Michael C Dalsing; Janet Klein; Michael G Wilson; Gary D Hutchins; Keith L March
Journal:  J Vasc Surg       Date:  2011-04-22       Impact factor: 4.268

2.  Domains that Determine Quality of Life in Vascular Amputees.

Authors:  Bjoern D Suckow; Philip P Goodney; Brian W Nolan; Ravi K Veeraswamy; Patricia Gallagher; Jack L Cronenwett; Larry W Kraiss
Journal:  Ann Vasc Surg       Date:  2015-02-26       Impact factor: 1.466

3.  Phase Ib Safety, Two-Dose Study of MultiGeneAngio in Patients with Chronic Critical Limb Ischemia.

Authors:  Moshe Y Flugelman; Moshe Halak; Boris Yoffe; Jacob Schneiderman; Chen Rubinstein; Allan-Isaac Bloom; Eran Weinmann; Ilya Goldin; Victor Ginzburg; Olga Mayzler; Aaron Hoffman; Belly Koren; Diana Gershtein; Michal Inbar; Marina Hutoran; Adili Tsaba
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

Review 4.  Limb ischemia: cardiovascular diagnosis and management from head to toe.

Authors:  Sreekanth Vemulapalli; Manesh R Patel; W Schuyler Jones
Journal:  Curr Cardiol Rep       Date:  2015-07       Impact factor: 2.931

5.  Lifelong limb preservation: A patient-centered description of lower extremity arterial reconstruction outcomes.

Authors:  Katie E Shean; Peter A Soden; Marc L Schermerhorn; Sara L Zettervall; Sarah E Deery; Jeremy D Darling; Allen Hamdan; Frank W LoGerfo
Journal:  J Vasc Surg       Date:  2017-05-11       Impact factor: 4.268

Review 6.  Diagnostics and treatment of the diabetic foot.

Authors:  Jan Apelqvist
Journal:  Endocrine       Date:  2012-02-25       Impact factor: 3.633

7.  Active smoking is associated with higher rates of incomplete wound healing after endovascular treatment of critical limb ischemia.

Authors:  Damianos G Kokkinidis; Stefanos Giannopoulos; Moosa Haider; Timothy Jordan; Anita Sarkar; Gagan D Singh; Eric A Secemsky; Jay Giri; Joshua A Beckman; Ehrin J Armstrong
Journal:  Vasc Med       Date:  2020-05-27       Impact factor: 3.239

Review 8.  Preventing and treating foot complications associated with diabetes mellitus.

Authors:  Frank L Bowling; S Tawqeer Rashid; Andrew J M Boulton
Journal:  Nat Rev Endocrinol       Date:  2015-08-18       Impact factor: 43.330

9.  A phase I study of human cord blood-derived mesenchymal stem cell therapy in patients with peripheral arterial occlusive disease.

Authors:  Shin-Seok Yang; Na-Ri Kim; Kwang-Bo Park; Young-Soo Do; Kyounghwan Roh; Kyung-Sun Kang; Dong-Ik Kim
Journal:  Int J Stem Cells       Date:  2013-05       Impact factor: 2.500

10.  Always contact a vascular interventional specialist before amputating a patient with critical limb ischemia.

Authors:  Rosemarie Met; Mark J W Koelemay; Shandra Bipat; Dink A Legemate; Krijn P van Lienden; Jim A Reekers
Journal:  Cardiovasc Intervent Radiol       Date:  2009-08-18       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.